Paper Review Records
All Paper Review Records
14 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
55
days
End-of-life care values and treatment preferences among Japanese breast cancer patients and families: A dyadic cross-sectional study
Authors
Akemi Hara; Ayu Ajitomi; Kazunoshin Tachibana; Kenji Gonda; Masahiro Wada; Rui Omori; Megumi Arai; Kayoko Konuma; Toyoaki Sawano; Yoshiaki Kanemoto; Hirotomo Miyatake; Tomohiro Kurokawa; Yukiko Kouchi; Norio Kanzaki; Yasuhiro Kotera; Yoshitake Takebayashi; Michio Murakami; Tohru Ohtake; Hiroaki Shimmura; Akihiko OzakiShow moreShow less
Affiliations
Clinical Research Center, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, North Cartolina, USA; Breast and Thyroid Center, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Department of Breast Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan; Department of Breast Surgery, Utsunomiya Central Clinic, Utsunomiya, Japan; Department of Breast Cancer, St. Luke's International Hospital, Tokyo, Japan; Department of Nursing, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Yushoukai Medical Corporation Nobishiroclinic, Fujisawa, Japan; Department of Urology, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; School of Health Sciences, Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom; Department of Health Risk Communication, Fukushima Medical University School of Medicine, Fukushima, Japan; Center for Infectious Disease Education and Research, The University of Osaka, Suita, Japan; EIPM Center, The University of Osaka, Suita, JapanShow moreShow less
56
days
Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer — from feasibility to precision practice
Authors
Yueting Tan; Benyuan Cheng; Kun He; Xiaobing XieShow moreShow less
Affiliations
Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China; The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, ChinaShow moreShow less
207
days
Molecular and immune profiling of HER2-low, HER2 ultra-low, and HER2-null male breast cancer
Authors
Dario Trapani; Sachin Kumar Deshmukh; Sharon Wu; Joanne Xiu; Priya Jayachandran; Shipra Gandhi; Nancy U. Lin; Giuseppe Curigliano; Philip M. Spanheimer; Daniel L. Abravanel; Milan Radovich; Maryam Lustberg; Stephanie L. Graff; George W. Sledge; Sara M. Tolaney; José P. LeoneShow moreShow less
Affiliations
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Caris Life Sciences, Phoenix, AZ, USA; El Camino Hospital, Mountain View, CA, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA; European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Yale School of Medicine, Yale University, New Haven, CT, USA; Lifespan Cancer Institute, Legorreta Cancer Center, Brown University, Providence, RI, USAShow moreShow less
66
days
Local treatment for HER2-positive or triple negative second ipsilateral breast cancer event: A propensity score-matched analysis of the GEC-ESTRO database
Authors
J.M. Hannoun-Levi; J. Gal; C. Weltens; V. Smanyko; D. Kauer-Domer; D. Pasquier; C. Lemanski; S. Racadot; G. Houvenaeghel; B. Guix; A. Belliere-Calandry; K. Loessl; B. Polat; C. Gutierrez; R. Galalae; C. Polgar; R. Schiappa; V. StrnadShow moreShow less
Affiliations
Department of Radiation Oncology, Antoine Lacassagne Cancer Centre, University of Côte d’Azur, Nice, France; University Côte d’Azur, Institut Hospitalo-Universitaire (IHU) RespirERA, 27 Rue du Professeur Delvalle, Nice, 06000, France; Department of Radiation Oncology, Radiation Oncology, University Hospital Gasthuisberg, Leuven, Belgium; Centre of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria; Department of Radiation Oncology, Oscar Lambret Cancer Centre, Lille University, Lille, France; Department of Radiation Oncology, Montpellier Cancer Institute, Montpellier, France; Department of Radiation Oncology, Leon Berard Cancer Centre, Lyon, France; Department of Surgical Oncology, Paoli-Calmettes Cancer Institute, Marseille, France; Department of Radiation Oncology, Medical Institute for Radiotherapy & Oncology, Barcelona, Spain; Department of Radiation Oncology, Auvergne Jean Perrin Cancer Centre, Clermont-Ferrand, France; Department of Radiation Oncology, Radiation Oncology, Inselspital, Bern University Hospital, Switzerland; Department of Radiation Oncology, Wurzburg University, Wurzburg, Germany; Department of Radiation Oncology, Hospital del Mar, Brachytherapy Unite, Catalan Institute of Oncology, Barcelona, Spain; MedAustron Centre for Ion Therapy and Research, Wiener Neustadt, Austria; Radiotherapy Centre, National Institute of Oncology, Budapest, Hungary; Department of Radiotherapy, Semmelweis University, Budapest, Hungary; Department of Radiation Oncology, Erlangen University Hospital, Erlangen, GermanyShow moreShow less
307
days
The genomic landscape of HER2 negative metastatic breast cancer with loss of estrogen and progesterone receptors
Authors
Ilenia Migliaccio; Marta Paoli; Chiara Biagioni; Cristina Guarducci; Francesca Galardi; Giulia Anichini; Laura Biganzoli; Matteo Benelli; Luca MalorniShow moreShow less
Affiliations
Translational Research Unit, Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Italy; Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy; Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Italy; Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, ItalyShow moreShow less
140
days
Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial
Authors
Frédérique Penault-Llorca; Amelie Lusque; Thomas Filleron; Kevin Tran; Lili Du; Rick Baehner; Florence Dalenc; Magali Lacroix-Triki; Thomas Bachelot; Fabrice Andre; Pascal Boucher; Jérôme Lemonnier; W. Fraser SymmansShow moreShow less
Affiliations
Department of Biopathology, Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, F-63000, France; Biostatistics & Health Data Science Unit, University of Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Exact Sciences, Madison, WI, USA; Department of Pathology, University of California, San Francisco, CA, USA; Department of Medical Oncology, Oncopole Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France; Department of Pathology, Institut Gustave Roussy, Villejuif, France; Department of Medical Oncology, Centre Leon Berard, Lyon, France; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Unicancer, Paris, FranceShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days